<DOC>
	<DOCNO>NCT00019773</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine oxaliplatin capecitabine treat patient colorectal , appendix , small bowel cancer .</brief_summary>
	<brief_title>Oxaliplatin Plus Capecitabine Treating Patients With Colorectal , Appendix , Small Bowel Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose ( MTD ) capecitabine administer oxaliplatin patient colorectal , appendiceal , small bowel cancer . - Determine clinical toxic effect associate regimen patient . - Characterize molecular profile tumor tissue obtain prior study entry determinant sensitivity regimen patient population . - Characterize molecular profile surrogate normal tissue ( bone marrow aspirate ) obtain prior treatment assess potential drug-associated induction DNA damage inhibition thymidylate synthase repeat bone marrow aspirate therapy . - Assess clinical activity regimen patient population . OUTLINE : This dose-escalation study capecitabine . Patients receive oxaliplatin IV 2 hour day 1 follow oral capecitabine twice daily day 1-5 8-12 . Courses repeat every 3 week absence unacceptable toxicity disease progression . Cohorts 3-6 patient receive escalate dos capecitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow every 3 month 6 month . PROJECTED ACCRUAL : A total 106 patient accrue study within 36 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Appendiceal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm colorectal , appendiceal , small bowel cancer Measurable disease No progression prior capecitabine No brain metastasis leptomeningeal carcinomatosis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin normal AST/ALT great 2.5 time upper limit normal Renal : Creatinine normal Creatinine clearance great 60 mL/min Cardiovascular : No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No sensory neuropathy No history allergy platinum compound No history allergy antiemetic appropriate administration study No history intolerance fluorouracil No uncontrolled concurrent illness would preclude study entry No ongoing active infection require IV antibiotic HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy recover Chemotherapy : See Disease Characteristics Recovered prior chemotherapy No 2 prior systemic chemotherapy regimens metastatic disease At least 6 week since prior nitrosoureas mitomycin At least 8 week since prior eniluracil At least 3 month since prior suramin At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Recovered prior radiotherapy At least 2 week since prior radiotherapy 20 % bone marrow reserve At least 4 week since prior radiotherapy least 21 % bone marrow reserve Surgery : Recovered prior surgery Other : At least 4 week since prior sorivudine brivudine recover No concurrent sorivudine brivudine No concurrent investigational agent No concurrent anticancer therapy commercial agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2003</verification_date>
	<keyword>stage I colon cancer</keyword>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage 0 colon cancer</keyword>
	<keyword>stage 0 rectal cancer</keyword>
	<keyword>stage I rectal cancer</keyword>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>small intestine adenocarcinoma</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>small intestine leiomyosarcoma</keyword>
	<keyword>recurrent small intestine cancer</keyword>
	<keyword>carcinoma appendix</keyword>
</DOC>